DE69428791T2 - Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten Atembeschwerden - Google Patents
Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten AtembeschwerdenInfo
- Publication number
- DE69428791T2 DE69428791T2 DE69428791T DE69428791T DE69428791T2 DE 69428791 T2 DE69428791 T2 DE 69428791T2 DE 69428791 T DE69428791 T DE 69428791T DE 69428791 T DE69428791 T DE 69428791T DE 69428791 T2 DE69428791 T2 DE 69428791T2
- Authority
- DE
- Germany
- Prior art keywords
- modafinil
- treatment
- sleep apnea
- sleep
- pct
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title claims abstract description 16
- 229960001165 modafinil Drugs 0.000 title claims abstract description 15
- 238000011282 treatment Methods 0.000 title claims abstract description 14
- 201000002859 sleep apnea Diseases 0.000 title claims abstract description 9
- 230000029058 respiratory gaseous exchange Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 208000035475 disorder Diseases 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 230000003519 ventilatory effect Effects 0.000 claims description 2
- 238000009423 ventilation Methods 0.000 abstract 1
- 208000008784 apnea Diseases 0.000 description 13
- 230000000694 effects Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 2
- 206010021079 Hypopnoea Diseases 0.000 description 2
- 206010038669 Respiratory arrest Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000014486 central sleep apnea syndrome Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020020 complex sleep apnea Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 238000000537 electroencephalography Methods 0.000 description 1
- 238000002567 electromyography Methods 0.000 description 1
- 238000002570 electrooculography Methods 0.000 description 1
- 201000006646 mixed sleep apnea Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 238000002496 oximetry Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrotherapy Devices (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Control Of Throttle Valves Provided In The Intake System Or In The Exhaust System (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9307555A FR2706767B1 (enExample) | 1993-06-22 | 1993-06-22 | |
| PCT/FR1994/000711 WO1995000132A1 (fr) | 1993-06-22 | 1994-06-14 | Utilisation du modafinil pour le traitement des apnees du sommeil et troubles ventilatoires d'origine centrale |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69428791D1 DE69428791D1 (de) | 2001-11-29 |
| DE69428791T2 true DE69428791T2 (de) | 2002-07-04 |
Family
ID=9448411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69428791T Expired - Lifetime DE69428791T2 (de) | 1993-06-22 | 1994-06-14 | Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten Atembeschwerden |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5612379A (enExample) |
| EP (1) | EP0705099B1 (enExample) |
| JP (1) | JP3703831B2 (enExample) |
| KR (1) | KR100315389B1 (enExample) |
| AT (1) | ATE207351T1 (enExample) |
| AU (1) | AU684087B2 (enExample) |
| CA (1) | CA2165824C (enExample) |
| DE (1) | DE69428791T2 (enExample) |
| DK (1) | DK0705099T3 (enExample) |
| ES (1) | ES2165878T3 (enExample) |
| FR (1) | FR2706767B1 (enExample) |
| HU (1) | HU216731B (enExample) |
| PT (1) | PT705099E (enExample) |
| WO (1) | WO1995000132A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618845A (en) | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
| JP2002504510A (ja) | 1998-02-27 | 2002-02-12 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ | 睡眠時無呼吸に対する処置のための、セロトニン関連活性を有する薬剤 |
| US7160898B2 (en) * | 2001-12-14 | 2007-01-09 | Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
| US20060241164A1 (en) * | 1998-02-27 | 2006-10-26 | The Board Of Trustees Of The University Of Illinoi | Pharmacological treatment for sleep apnea |
| US6492396B2 (en) | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
| JP4593074B2 (ja) * | 2000-10-11 | 2010-12-08 | セフアロン・インコーポレーテツド | モダフィニル化合物含有組成物 |
| US20080058424A1 (en) * | 2002-05-23 | 2008-03-06 | Cephalon, Inc. | Novel pharmaceutical formulations of modafinil |
| US7297346B2 (en) * | 2001-05-25 | 2007-11-20 | Cephalon Inc. | Pharmaceutical formulations of modafinil |
| US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
| US20040048931A1 (en) | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
| US6992219B2 (en) * | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
| US20040116532A1 (en) * | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| IL153098A0 (en) * | 2002-11-26 | 2003-06-24 | Chemagis Ltd | Pharmaceutical compositions containing modafinil |
| US7528172B2 (en) * | 2003-01-21 | 2009-05-05 | The Cooper Health System, Inc. | Compositions and methods for improving recovery after general anesthesia |
| ES2487415T3 (es) * | 2003-03-17 | 2014-08-20 | Neurohealing Pharmaceuticals, Inc. | Tratamiento dopaminérgico de alta potencia de deficiencias neurológicas asociadas con lesiones cerebrales |
| US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
| AR045423A1 (es) * | 2003-05-13 | 2005-10-26 | Cephalon Inc | Combinaciones de analiticos y antidepresivos |
| US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
| US7119214B2 (en) * | 2004-04-13 | 2006-10-10 | Cephalon France | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
| EP1586560A1 (en) * | 2004-04-13 | 2005-10-19 | Cephalon, Inc. | Thio-substituted arylmethanesulfinyl derivatives |
| US7423176B2 (en) * | 2004-04-13 | 2008-09-09 | Cephalon, Inc. | Bicyclic aromatic sulfinyl derivatives |
| US7449481B2 (en) * | 2004-04-13 | 2008-11-11 | Cephalon, Inc. | Thio-substituted biaryl-methanesulfinyl derivatives |
| US7314875B2 (en) * | 2004-04-13 | 2008-01-01 | Cephalon, Inc. | Tricyclic aromatic and bis-phenyl sulfinyl derivatives |
| US7297817B2 (en) * | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
| WO2006069030A1 (en) * | 2004-12-20 | 2006-06-29 | Collegium Pharmaceutical, Inc. | Pharmaceutical compositions for sleep disorders |
| AU2006272874B2 (en) * | 2005-07-21 | 2010-03-11 | Neurohealing Pharmaceuticals, Inc. | Rapid onset and short term modafinil compositions and methods of use thereof |
| BRPI0714173A2 (pt) * | 2006-07-12 | 2012-12-25 | Elan Pharma Int Ltd | composiÇço nanoparticulada estÁvel,mÉtodos para preparar a composiÇço, para prevenir e/ou tratar estados de doenÇas, sintomas, sÍndromes e condiÇÕes do sistema nervoso central, para melhorar ou manter a biodisponibilidade de modafinil, e para tratar distérbio com base neurolàgica, composiÇço farmacÊutica, e forma de dosagem |
| JP5395663B2 (ja) | 2006-08-14 | 2014-01-22 | ニューロヒーリング・ファーマシューティカルズ・インコーポレーテッド | モダフィニルによる早漏の治療 |
| US20080181966A1 (en) * | 2006-10-18 | 2008-07-31 | Cephalon, Inc. | Modafinil pharmaceutical compositions |
| CN101641090B (zh) * | 2006-12-19 | 2012-12-05 | 亚勒斯有限公司 | 莫达非尼在制备治疗多动腿综合征的药物中的应用 |
| AU2011203970A1 (en) * | 2010-01-07 | 2012-07-12 | Vivus, Inc. | Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent |
| ES2871381T3 (es) | 2013-08-30 | 2021-10-28 | Green Cross Wellbeing Corp | Composición para prevenir y tratar la fatiga relacionada con el cáncer, que contiene polvo de ginseng procesado o extracto de ginseng procesado que tiene un componente de ginsenósido mejorado |
| US9616068B2 (en) | 2014-10-27 | 2017-04-11 | Pohela LLC | Animal training using cognitive enhancement |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1584462A (en) * | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
| FR2663225B1 (fr) * | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
| FR2684875B1 (fr) * | 1991-12-13 | 1995-05-24 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique. |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
-
1993
- 1993-06-22 FR FR9307555A patent/FR2706767B1/fr not_active Expired - Fee Related
-
1994
- 1994-06-14 JP JP50249895A patent/JP3703831B2/ja not_active Expired - Lifetime
- 1994-06-14 AT AT94919708T patent/ATE207351T1/de active
- 1994-06-14 US US08/564,286 patent/US5612379A/en not_active Expired - Lifetime
- 1994-06-14 DE DE69428791T patent/DE69428791T2/de not_active Expired - Lifetime
- 1994-06-14 HU HU9503702A patent/HU216731B/hu unknown
- 1994-06-14 EP EP94919708A patent/EP0705099B1/fr not_active Expired - Lifetime
- 1994-06-14 ES ES94919708T patent/ES2165878T3/es not_active Expired - Lifetime
- 1994-06-14 WO PCT/FR1994/000711 patent/WO1995000132A1/fr not_active Ceased
- 1994-06-14 CA CA002165824A patent/CA2165824C/fr not_active Expired - Lifetime
- 1994-06-14 KR KR1019950705833A patent/KR100315389B1/ko not_active Expired - Fee Related
- 1994-06-14 DK DK94919708T patent/DK0705099T3/da active
- 1994-06-14 AU AU70760/94A patent/AU684087B2/en not_active Expired
- 1994-06-14 PT PT94919708T patent/PT705099E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE207351T1 (de) | 2001-11-15 |
| KR100315389B1 (ko) | 2002-02-19 |
| JP3703831B2 (ja) | 2005-10-05 |
| WO1995000132A1 (fr) | 1995-01-05 |
| CA2165824C (fr) | 2005-08-02 |
| KR960703009A (ko) | 1996-06-19 |
| PT705099E (pt) | 2002-03-28 |
| AU7076094A (en) | 1995-01-17 |
| CA2165824A1 (fr) | 1995-01-05 |
| DE69428791D1 (de) | 2001-11-29 |
| EP0705099A1 (fr) | 1996-04-10 |
| EP0705099B1 (fr) | 2001-10-24 |
| JPH09500374A (ja) | 1997-01-14 |
| HU216731B (hu) | 1999-08-30 |
| ES2165878T3 (es) | 2002-04-01 |
| AU684087B2 (en) | 1997-12-04 |
| FR2706767A1 (enExample) | 1994-12-30 |
| HUT74674A (en) | 1997-01-28 |
| US5612379A (en) | 1997-03-18 |
| HU9503702D0 (en) | 1996-02-28 |
| DK0705099T3 (da) | 2002-02-11 |
| FR2706767B1 (enExample) | 1995-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69428791T2 (de) | Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten Atembeschwerden | |
| Becker et al. | Reversal of sinus arrest and atrioventricular conduction block in patients with sleep apnea during nasal continuous positive airway pressure. | |
| Kribbs et al. | Effects of one night without nasal CPAP treatment on sleep and sleepiness in patients with obstructive sleep apnea | |
| Chan et al. | Nocturnal asthma: role of snoring and obstructive sleep apnea | |
| Rapoport et al. | Hypercapnia in the obstructive sleep apnea syndrome: a reevaluation of the “Pickwickian syndrome” | |
| DE69829112T2 (de) | Butyrate Derivate zur Behandlung von Fibromyalgia und chronischem Müdigkeits-Syndrom | |
| Remmers | Obstructive sleep apnea: a common disorder exacerbated by alcohol | |
| Raval et al. | Oral clonidine pre medication for attenuation of haemodynamic response to laryngoscopy and intubation | |
| Badr et al. | Treatment of refractory sleep apnea with supplemental carbon dioxide. | |
| DE60111025T2 (de) | Verwendung von Topiramat zur Behandlung und Diagnostizierung von Atemstörungen während des Schlafens und Mittel zur Durchführung der Behandlung und Diagnose | |
| Tønnesen et al. | Bronchodilating effect of terbutaline powder in acute severe bronchial obstruction | |
| DE69201660T2 (de) | Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma. | |
| Illman et al. | Reversal of neuromuscular blockade by sugammadex does not affect EEG derived indices of depth of anesthesia | |
| Adams et al. | Hysteria: a cause of failure to recover after anaesthesia | |
| Avital et al. | Sleep quality in children with asthma treated with theophylline or cromolyn sodium | |
| DE60100660T2 (de) | Verwendung von modafinil zur herstellung eines arzneimittels zur behandlung von vigilanzstörungen im zusammenhang mit myopathien | |
| Grippo et al. | Cortical excitability in obstructive sleep apnea syndrome: transcranial magnetic stimulation study | |
| Tammisto et al. | A comparison of Althesin and thiopentone in induction of anaesthesia | |
| Barr et al. | IV sedation in pediatric dentistry: an alternative to general anesthesia | |
| Kaufman et al. | Staircase assessment of the magnitude and time-course of 50% nitrous-oxide analgesia | |
| Yokoe et al. | The effect of nitrous oxide inhalation on the hypotensive response to propofol: a randomized controlled trial | |
| Brundidge et al. | EEG-controlled “overdosage” of anesthetics in a patient with a history of intra-anesthetic awareness | |
| Pankow et al. | Continuous positive airway pressure lowers blood pressure in hypertensive patients with obstructive sleep apnea | |
| Blinn et al. | Pancuronium dose‐response revisited | |
| KumAri et al. | Effect of Preoperative Preconditioning of Patients with External Nasal Compression for Different Time Intervals on Emergence Agitation After Nasal Surgeries: A Randomised Controlled Trial. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |